Skip to main content

Table 5 Intermediate and cumulative systems effectiveness of delivery of ISTp-DP

From: Intermittent screening and treatment with dihydroartemisinin-piperaquine for the prevention of malaria in pregnancy: implementation feasibility in a routine healthcare system setting in western Kenya

IST arm (N = 360)a

N

n

Intermediate process effectiveness, % (95% CI)

Cumulative delivery effectiveness, %

1. 2nd or 3rd trimester women

347

347

100

100

2. Given an RDT testb

320

289

90.3 (70.7, 97.3)

90.3

3a. RDT negative

289

257

88.9 (84.3, 92.3)

90.3

3b. RDT −ve not given any drug

211

211

100

90.3 (3b = tested − ve)

4a. RDT +ve

289

32

11.1 (7.7, 15.7)

90.3

4b. RDT+ ve given any DP

32

29

90.6 (59.8, 98.4)

81.8

5. DP given at correct dosec

29

25

86.2 (56.5, 96.8)

70.5

6. Given stat dose by DOT

25

11

44.0 (15.0, 77.7)

31.0

7. Correct no. tablets taken

11

11

100

31.0

8. Health worker describe to woman how to take remaining doses

11

2

0

5.6

9. Woman able to repeat instructions

2

0

 

0 (9 = tested+ ve)

10. Composite endpoint

347

211

 

60.8

  1. aAnalysis limited to participants who were not given any antiretroviral and who did not report having a fever
  2. b27 missing
  3. cDP dose based on weight, stat dose given by DOT and remaining two doses given to take home—24 to 35.9 kg, 2 tablets; 36 to 74.9 kg, 3 tablets; > 75 kg, 4 tablets